Molecular Biology in Breast Oncology - Hemisfair Ballroom - 3rd Level
Moderator: Carlos L. Arteaga, MD
UT Southwestern 
Simmons Comprehensive Cancer Center
Dallas, TX

Novel targets in breast cancer: How to go about drugging them?
Lori S. Friedman, PhD
Genentech, Inc.
South San Francisco, CA

Circulating tumor DNA analysis to elucidate drug action & resistance
Nicholas Turner, PhD, FRCP
Institute of Cancer Research/The Royal Marsden Hospital
London, UNITED KINGDOM

The breast tumor microenvironment: Clinical implications for checkpoint inhibitors
Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Molecular heterogeneity of TNBC: Biological implications
Samuel Aparicio, BM, BCh, PhD, FRCPath
University of British Columbia
Vancouver, CANADA

Clinical Research - Stars at Night Ballroom 2&3 - 3rd Level
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

            Phase 1 clinical trials: Is there more than 3+3?
            Susan G. Hilsenbeck, PhD
            Baylor College of Medicine
            Houston, TX

FDA perspectives: Molecular diagnostics
Reena Philip, PhD
US Food and Drug Administration
Silver Spring, MD

Incorporating patient reported outcomes and functional measures into
clinical trials
Jennifer A. Ligibel, MD
Dana-Farber Cancer Institute
Boston, MA

Design of immunotherapeutic trials in breast cancer
Sherene Loi, MBBS (Hons), FRACP, PhD, FAHMS
Peter MacCallum Cancer Centre
Melbourne, AUSTRALIA

EDUCATIONAL SESSIONS - Stars at Night Ballrooms 1, 2&3, 4 and Hemisfair Ballroom  - 3rd Level

Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. These presentations should also provide researchers with ideas and techniques to be considered for their own studies.

Twenty Years of Targeting HER2: Where Are We Now? – Hemisfair Ballroom - 3rd Level
Moderator: Mothaffar F. Rimawi, MD
Baylor College of Medicine
Houston, TX

What is a HER2-positive in breast cancer in 2018?
Stuart J. Schnitt, MD
Brigham and Women's Hospital 
Dana-Farber Cancer Institute
Boston, MA

Early HER2-positive breast cancer: Doing more and less
Lisa A. Carey, MD
UNC - Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Advanced HER2-positive breast cancer: Overcoming treatment resistance
Mothaffar F. Rimawi, MD
Baylor College of Medicine
Houston, TX

Insights and Controversies in Metastasis Biology - Stars at Night Ballroom 1 - 3rd Level
Moderator: Michael Lewis, PhD
Baylor College of Medicine
Houston, TX

            The EMT and metastasis controversy: Where things stand in 2018
            Heide L. Ford, PhD
            University of Colorado School of Medicine
            Aurora, CO

            Breast cancer's metastatic moment: How postpartum tissue involution
            facilitates progression
            Pepper J. Schedin, PhD
            Oregon Health and Science University
            Portland, OR

            Exosome-mediated stimulation of metastasis
            Andy J. Minn, MD
            University of Pennsylvania
            Philadelphia, PA

Contemporary Management of Breast Cancer Brain Metastases – Stars at Night Ballroom 2&3 - 3rd Level
Moderator:  Nancy U. Lin, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Brain metastases of breast cancer
Patricia S. Steeg, PhD
National Cancer Institute
Bethesda, MD

Multidisciplinary management of breast cancer brain metastases
Christina I. Tsien, MD
Washington University
St. Louis, MO

Systemic therapy for breast cancer brain metastases
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA

Partial Breast Irradiation - Where Does it Stand? ‐ Stars at Night Ballroom 4 - 3rd Level
Moderator: Richard Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX

            Partial breast irradiation: Efficacy and patient selection
            Charlotte Coles, MB ChB, MRCP, FRCR, PhD
            University of Cambridge
            Cambridge, UNITED KINGDOM

Treatment morbidity and quality of life considerations
Timothy J. Whelan, BSc, BM, BCh, MSc, FRCPC
McMaster University
Hamilton, CANADA

Techniques and technical considerations
Frank A. Vicini, MD, FACR, FABS, FASTRO
MHP Radiation Oncology Institute
Farmington Hills, MI

3:45 pm - 5:15 pm

Late Recurrence in ER Positive Breast Cancer: Therapeutic Interventions and Biological Insights – Hemisfair Ballroom - 3rd Level
Moderator:  Matthew J. Ellis, MD, PhD
Baylor College of Medicine
Houston, TX

Tumor dormancy and recurrence
Lewis A. Chodosh, MD, PhD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Clinical and molecular profiles to identify who is at risk?
Mitchell Dowsett, PhD
Ralph Lauren Centre for Breast Cancer Research
London, UNITED KINGDOM

Late recurrence in ER-positive breast cancer
Julie R. Gralow, MD
University of Washington
Seattle, WA

Metabolic Reprogramming in Breast Cancer – Stars at Night Ballroom 1 - 3rd Level
Moderator: Alexander Bishop, DPhil, BSc
Greehey Children's Cancer Research Institute
UT Health San Antonio
San Antonio, TX

Oxidative stress responses in cancer
Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

PI3K in breast cancer, glutamine changes and methionine addiction 
Alex Toker, PhD
Beth Israel Deaconess Medical Center
Boston, MA

Systems approaches to attacking cancer vulnerabilities defined by metabolic, de-differentiation and genomic instability states
Thomas G. Graeber, PhD
University of California Los Angeles
Los Angeles, CA

Management of the Axilla after Neoadjuvant Therapy: Beyond the Clinical Trials – Stars at Night Ballroom 2&3 - 3rd Level
Moderator:  Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Methods to minimize the false negative rate of sentinel lymph node surgery after neoadjuvant chemotherapy for node positive breast cancer
Judy C. Boughey, MD
Mayo Clinic
Rochester, MN

Practical approach to the axilla after neoadjuvant chemotherapy: What the clinical trials don't address
Andrea V. Barrio, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Indications for radiation treatments after neoadjuvant chemotherapy while awaiting the results of clinical trials
Thomas A. Buchholz, MD
Scripps Health
San Diego, CA

Exposures Throughout the Lifecourse - New Data on The Environment, Hormones, and Alcohol - Stars at Night Ballroom 4 - 3rd Level
Moderator: Melissa L. Bondy, PhD
Baylor College of Medicine
Houston, TX

Windows of susceptibility across the lifecourse and breast cancer
Lawrence H. Kushi, ScD
Kaiser Permanente Northern California
Oakland, CA

New data on hormones and risk of breast cancer
Susan E. Hankinson, ScD
University of Massachusetts
Amherst, MA

Does breast cancer prevention need an 18th amendment? New evidence on alcohol and breast cancer
Mary Beth Terry, PhD
Columbia University
New York, NY

5:30 pm - 7:00 pm

Updates in the Treatment of Triple Negative Breast Cancer - Hemisfair Ballroom - 3rd Level
Moderator:  Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Optimizing treatment of early stage triple negative breast cancer: Clinical challenges and new scientific horizons
Angela DeMichele, MD, MSCE
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Updates on immunotherapy for TNBC
Sylvia Adams, MD
New York University
New York, NY

Triple negative breast cancer: Current and future directions in metastatic patients
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX

Translational Insights in Estrogen Receptor Signaling and Endocrine Resistance - Bench to Bedside – Stars at Night Ballroom 1 - 3rd Level
Moderator:  Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Recurrent ESR1 mutations activating mutations in breast cancer
Rinath M. Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

Mining noncoding mutations for drivers of development in ER alpha-positive
breast cancer
Mathieu Lupien, PhD
Princess Margaret Cancer Centre
Toronto, CANADA

Blockade of estrogen signaling boosts antitumor immunity by inhibiting
tumor-induced pathological myelopoiesis
Jose Conejo-Garcia, MD, PhD
H. Lee Moffitt Cancer Center
Tampa, FL

Managing Lymphedema in 2018: Can We Forgo the Sleeve?- Stars at Night Ballroom 2&3 - 3rd Level
Moderator:  Bhuvaneswari Ramaswamy, MBBS, MRCP
Ohio State University
Columbus, OH

Lymphedema management in 2018: Are we making any progress?
Babak J. Mehrara, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Current status of diagnosis, monitoring, and non-surgical management of lymphedema
Sarah A. McLaughlin, MD
Mayo Clinic
Jacksonville, FL

Microsurgical treatment of lymphedema
David W. Chang, MD, FACS
University of Chicago
Chicago, IL

BRCA 1/2: Beyond DNA Repair - Stars at Night Ballroom 4 - 3rd Level
Moderator: Ratna K. Vadlamudi, PhD
UT Health San Antonio
San Antonio, TX

Linking cancer pathogenesis to emerging functions of the BRCA proteins beyond DNA repair
Ashok Venkitaraman, MBBS, PhD
MRC Cancer Unit
University of Cambridge
Cambridge, UNITED KINGDOM

Link between BRCA1 and Pol II pausing in mammary gland development and
tumorigenesis
Rong Li, PhD
The George Washington University
Washington, DC

BRCA1/2/3 and p53 in replication fork stability
Katharina Schlacher, PhD
UT MD Anderson Cancer Center
Houston, TX

REGISTRATION - Main Lobby

WELCOME AND OPENING REMARKS - Hall 3
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Breast Tumor Evolution and Intratumor Heterogeneity - Insights from Single Cell Genomics
Nicholas E. Navin, PhD
UT MD Anderson Cancer Center
Houston, TX

GENERAL SESSION 1 - Hall 3

WILLIAM L. MCGUIRE MEMORIAL LECTURE – Hall 3

BREAK

Cancer Genetics: Updates for Breast Cancer Care
Moderator: Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Polygenic risk scores for breast cancer: Ready or not?
D. Gareth Evans, FRCP, MD, MBBS
University of Manchester
Manchester, UNITED KINGDOM

Breast cancer genetic testing and results in diverse populations
Allison W. Kurian, MD, MSc
Stanford University School of Medicine
Stanford, CA

Moderate penetrance mutations: What to do?
Susan M. Domchek, MD
University of Pennsylvania
Philadelphia, PA

Peering into Tumor-Microenvironment Interaction in Metastasis
Moderator: Yi Li, PhD
Baylor College of Medicine
Houston, TX

High resolution intravital imaging of the mechanism of how breast cancer initiates and sustains systemic dissemination
John S. Condeelis, PhD
Albert Einstein College of Medicine
Bronx, NY

Neutrophil extracellular traps promote breast cancer metastasis
Mikala Egeblad, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY

New insights into early-stage bone colonization of disseminated breast cancer cells
Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

GENERAL SESSION 2 - Hall 3

POSTER SESSION 1 & Reception - Hall 1 

REGISTRATION - Main Lobby

POSTER SESSION 2 & continental breakfast - Hall 1

Neoadjuvant Endocrine Therapy: The Times They are A-Changing
Ingrid A. Mayer, MD, MSCI
Vanderbilt University Medical Center
Nashville, TN

GENERAL SESSION 3 - Hall 3

CASE DISCUSSION 1 - Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

TRANSLATIONAL SCIENCE FORUM 2 - Stars at Night Ballroom 3&4 - 3rd Level

PI3K Pathway in Breast Cancer
Moderator: Carlos L. Arteaga, MD
UT Southwestern
Simmons Comprehensive Cancer Center
Dallas, TX

The complexity of targeting PI3K for cancer therapy
Lewis C. Cantley, PhD
The Sandra and Edward Meyer Cancer Center
New York, NY

Clinical development of inhibitors of the PI3K pathway
Cristina Saura Manich, MD, PhD
Vall d'Hebron University Hospital
Barcelona, SPAIN

Lessons learned from the development of PI3K inhibitors in metastatic breast cancer
Dejan Juric, MD
Massachusetts General Hospital
Boston, MA 

Man vs. Machine: Now and in the Future
Moderator: Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX

Deep learning systems for reading mammograms and breast tomosynthesis

Nico Karssemeijer, PhD
Radboud University Medical Centre
Nijmegen, NETHERLANDS

Artificial intelligence to optimize the accuracy and predictiveness of breast cancer pathology
Andrew H. Beck, MD, PhD
PathAI
Cambridge, MA

GENERAL SESSION 4 - Hall 3

POSTER SESSION 3 & Reception - Hall 1

REGISTRATION - Main Lobby

POSTER SESSION 4 & continental breakfast - Hall 1

DEBATE - Hall 3

Should All Women with Breast Cancer and Positive Lymph Nodes Receive Chemotherapy?
Chairman: Clifford A. Hudis, MD
American Society of Clinical Oncology
Alexandria, VA

Daniel Hayes, MD, FASCO, FACP
University of Michigan
Ann Arbor, MI

Harold Burstein, MD, PhD
Dana-Farber Cancer Institute
Boston, MA 

GENERAL SESSION 5 - Hall 3

2018 AACR OUTSTANDING INVESTIGATOR AWARD IN BREAST CANCER RESEARCH, SUPPORTED BY THE BREAST CANCER RESEARCH FOUNDATION - Hall 3

BREAK

CASE DISCUSSION 2 - Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

TRANSLATIONAL SCIENCE FORUM 3 – Stars at Night Ballroom 3&4 - 3rd Level

Interplay Between Breast Cancer Targeted Therapies and the Immune System
Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

Beyond B cells: Targeting BCL-2 pro-survival proteins in breast cancer 
Geoffrey Lindeman, MBBS, FRACP, PhD
Walter and Eliza Hall Institute of Medical Research
Parkville, AUSTRALIA

Modulation of anti-tumor immunity using CDK4/6 inhibitors
Shom Goel, B Med Sci, MBBS, FRACP, PhD
Dana-Farber Cancer Institute
Boston, MA

Over and Under Treatment: Getting It Right for Each Patient
Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Overtreatment: First, do no harm
Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Missed opportunities - The perils of under-treatment
Rachel A. Freedman, MD, MPH
Dana-Farber Cancer Institute
Boston, MA 

GENERAL SESSION 6 - Hall 3

POSTER SESSION 5 & Reception - Hall 1 

SPECIAL SESSION - Stars at Night Ballroom 3&4 - 3rd Level

Registration - Main Lobby

The Year in Review - Hall 3

Moderator:  C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX 

Basic science
Robert Benezra, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Translational research
Andrew Tutt, FRCR, PhD
Institute of Cancer Research
London, UNITED KINGDOM         

Early stage breast cancer, Year in Review: Evolving paradigms
Priyanka Sharma, MBBS
University of Kansas Medical Center
Westwood, KS

Metastatic breast cancer
Roisin M. Connolly, MBBCh, MD
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, MD